CORDIS
EU research results

CORDIS

English EN

A Phase Ib/II study of MEK1/2 inhibitor PD-0325901 or MEK-162 with cMET inhibitor PF-02341066 in RASMT and RASWT (with aberrant c-MET) Colorectal Cancer Patients

Project information

Grant agreement ID: 602901

Status

Ongoing project

  • Start date

    1 December 2013

  • End date

    30 November 2020

Funded under:

FP7-HEALTH

  • Overall budget:

    € 7 944 883,95

  • EU contribution

    € 5 999 994,60

Coordinated by:

THE QUEEN'S UNIVERSITY OF BELFAST

United Kingdom

Objective

Colorectal cancer (CRC) is the 3rd most common cancer in Europe, and with approximately 200,000 deaths per year, it remains the 2nd most common cause of cancer death. More than half of all CRC patients develop distant metastases and have 5-year overall survival (OS) of less than 5% because of ineffective treatments. Increased understanding of cancer biology, coupled with the implementation of “omics”-based approaches, has revealed that cancer must be considered a heterogeneous disease. Historically, “one-size-fits-all” approaches have been standard practice in CRC treatment, but with the increased understanding of the molecular/genetic heterogeneity of CRC, it is clear that novel treatments must be developed and tested in selected subgroups to maximize the benefit of these new developments. MErCuRIC is a multicentre phase Ib/II clinical trial which will assess a novel therapeutic strategy (combined treatment of a MEK inhibitor PD-0325901 or MEK-162 with a MET inhibitor PF-02341066) to combat metastasis, improve survival and change current clinical practice for CRC patients with RAS mutant (MT) and RAS wild type (WT) (with aberrant c-MET) tumours. The consortium will go beyond the current state-of-the-art by (i) employing a novel treatment strategy targeting the biology of the disease and by (ii) using next generation sequencing (NGS) and ‘xenopatients’ to identify CRC patient subgroups who will maximally benefit from this novel treatment strategy.
Leaflet | Map data © OpenStreetMap contributors, Credit: EC-GISCO, © EuroGeographics for the administrative boundaries

Coordinator

THE QUEEN'S UNIVERSITY OF BELFAST

Address

University Road Lanyon Building
Bt7 1nn Belfast

United Kingdom

Activity type

Higher or Secondary Education Establishments

EU Contribution

€ 415 289,88

Administrative Contact

Colleen Spence (Mrs.)

Participants (12)

FUNDACIO PRIVADA INSTITUT D'INVESTIGACIO ONCOLOGICA DE VALL-HEBRON

Spain

EU Contribution

€ 431 625,22

THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD

United Kingdom

EU Contribution

€ 1 486 544,38

UNIVERSITAIR ZIEKENHUIS ANTWERPEN

Belgium

EU Contribution

€ 430 946,28

VELINDRE NATIONAL HEALTH SERVICE TRUST

United Kingdom

EU Contribution

€ 330 183,09

ROYAL COLLEGE OF SURGEONS IN IRELAND

Ireland

EU Contribution

€ 330 183,09

UNIVERSITE PARIS DESCARTES

France

EU Contribution

€ 210 200

UNIVERSITA DEGLI STUDI DI TORINO

Italy

EU Contribution

€ 711 319

ASSISTANCE PUBLIQUE HOPITAUX DE PARIS

France

EU Contribution

€ 659 994,44

MULTIPLICOM NV

Belgium

EU Contribution

€ 193 880,20

Masarykova univerzita

Czechia

EU Contribution

€ 200 595

PINTAIL LTD

Ireland

EU Contribution

€ 165 925,20

BELFAST HEALTH AND SOCIAL CARE TRUST

United Kingdom

EU Contribution

€ 433 308,82

Project information

Grant agreement ID: 602901

Status

Ongoing project

  • Start date

    1 December 2013

  • End date

    30 November 2020

Funded under:

FP7-HEALTH

  • Overall budget:

    € 7 944 883,95

  • EU contribution

    € 5 999 994,60

Coordinated by:

THE QUEEN'S UNIVERSITY OF BELFAST

United Kingdom